Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma, Inc. (Nasdaq: COCP) will present data from its Phase 1 clinical trial of CC-42344, a novel antiviral targeting influenza A, at the upcoming World Antiviral Congress on December 1, 2022. Dr. Sam Lee, co-interim CEO, expressed excitement about sharing this first-in-human trial data, which aims to address both seasonal and pandemic influenza. The company plans to initiate a Phase 2a human challenge trial, leveraging advanced antiviral technology with a promising safety profile. The global influenza therapeutics market is expected to grow, reaching $9.5 billion by 2027.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has chosen its antiviral drug candidate CDI-988 for clinical development as an oral treatment for COVID-19. This candidate targets a key region in the SARS-CoV-2 main protease, showcasing superior in vitro potency compared to competitors. With favorable safety and pharmacokinetic profiles, CDI-988 is positioned for a first-in-human trial in Australia anticipated in Q1 2023, following IND-enabling toxicology studies. Cocrystal aims to advance antiviral therapeutics to combat various viral diseases.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, at 1:00 p.m. Eastern time. The event is scheduled at the Wyndham Grand Hotel in Jupiter, Florida. Mr. Martin will also be available for one-on-one meetings throughout the conference. The presentation will be accessible on the company's website starting October 12.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a 1-for-12 reverse stock split approved by its Board of Directors, effective October 11, 2022. This move aims to maintain compliance with Nasdaq Rule 5550(a)(2), which requires share prices to be above $1.00 for 30 consecutive trading days to avoid delisting. Following the split, the outstanding shares will decrease from approximately 97.5 million to around 8.1 million, while the authorized shares remain at 150 million. No fractional shares will be issued, and existing equity awards will be proportionately adjusted.

Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, via a hybrid model. James Martin, CFO and interim co-CEO, will present on-demand starting September 12 at 7:00 a.m. ET. Attendees can engage in virtual one-on-one meetings throughout the conference. Interested investors and industry professionals can register for attendance.

Cocrystal Pharma (Nasdaq: COCP) reported its Q2 2022 financial results and updates on antiviral pipeline developments. The company is advancing its oral PB2 inhibitor CC-42344, with a Phase 2a study planned to evaluate its efficacy against influenza A. Recent pharmacokinetic data supports once-daily dosing for CC-42344. Collaboration with NIAID is ongoing for COVID-19 protease inhibitors, with plans for two Phase 1 studies this year. Financially, Cocrystal faced a net loss of $24.4 million in Q2, including a $19.1 million non-cash goodwill impairment due to stock price decreases.

Cocrystal Pharma (Nasdaq: COCP) has completed the single ascending dose portion of its Phase 1 study for the antiviral candidate CC-42344, showing favorable pharmacokinetic data that supports once-daily dosing potential. The study, conducted in Australia, aims to assess safety and tolerability in healthy adults. Preliminary data indicated a positive safety profile for doses of 100 mg and 200 mg. CC-42344 acts as a PB2 inhibitor and demonstrates antiviral activity against resistant influenza A strains, potentially outperforming existing treatments like Tamiflu.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies on its 3CL protease inhibitors for COVID-19 treatment. This collaboration will support the scale-up synthesis of a key intermediate necessary for the development of these inhibitors. Cocrystal aims to create antiviral drugs targeting viral replication proteins, potentially beneficial against various coronaviruses, including COVID-19.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that James Martin, Chief Financial Officer and co-interim CEO, will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 a.m. Eastern Time. This hybrid event will take place at the Fontainebleau Miami Beach Hotel. A live webcast of the presentation will be available on the company’s IR Calendar and archived for 90 days.

Cocrystal specializes in developing antiviral therapeutics targeting influenza, coronaviruses, and more.